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serum and extracellular Vesicle 
Micrornas mir-423, mir-199,  
and mir-93* as Biomarkers for  
acute graft-versus-host Disease
Rachel E. Crossland1, Jean Norden1, Mateja Kralj Juric2, Kim F. Pearce1, Clare Lendrem1, 
Louis A. Bibby1, Matthew Collin1, Hildegard T. Greinix3 and Anne M. Dickinson1*
1 Medical School, Institute for Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, 2 Department 
of Internal Medicine I, Medical University of Vienna, Vienna, Austria, 3 Division of Hematology, Medical University of Graz, 
Graz, Austria
Acute graft-versus-host disease (aGvHD) is a major cause of adverse outcome in 
hematopoietic stem cell transplantation (HSCT), with a high incidence (20–50%). 
A novel, non-invasive diagnostic test to predict for prevalence and severity would enable 
improved prophylaxis and reduce morbidity. Circulatory microRNAs (miRNAs) miR-423, 
miR-199, miR-93*, and miR-377 have previously been associated with aGvHD in post-
HSCT patient plasma, but validation is lacking and their expression within extracellular 
vesicles (EVs) has not been explored. This study replicated elevated serum expression of 
miR-423 (p < 0.001), miR-199 (p = 0.04), miR-93* (p < 0.001), and miR-377 (p = 0.03) in 
aGvHD, using a prognostic cohort of day 14 (D14) post-HSCT patient samples (n = 81). 
Expression also associated with disease severity. Further analysis at aGvHD diagnosis in 
an independent cohort (n = 65) confirmed high miR-423 (p = 0.02), miR-199 (p = 0.007), 
and miR-93* (p = 0.004) expression at disease onset. Investigation of expression pat-
terns during early HSCT sequential timepoints (pre-HSCT to D28) identified elevated 
miRNAs at D7 post-HSCT in all transplant patients. In a novel investigation of miRNA 
expression in serum EVs (n = 15), miR-423 (p = 0.09), miR-199 (p = 0.008), and miR-93* 
(p = 0.001) levels were lower at D14 in patients who later developed aGvHD, and this 
was replicated for miR-423 (p = 0.02) and miR-199 (p = 0.04) (n = 47). Comparing 
serum to circulating EVs, at D14 patients remaining aGvHD-free had higher expression 
of miR-423 (p = 0.03), miR-199 (p = 0.009), and miR-93* (p = 0.002) in the EV fraction. 
Results verify the capacity for circulating miR-423, miR-199, and miR-93* as diagnostic 
and prognostic aGvHD biomarkers. The novel finding of their differential expression in 
EVs suggests a potential role in aGvHD etiology.
Keywords: graft-versus-host disease, biomarkers, prognosis, microrna, extracellular vesicles
KeY POinTs
•	 Expression	of	miR-423,	miR-199,	and	miR-93*	in	post-HSCT	serum	and	extracellular	vesicles	is	
associated	with	aGvHD	incidence	and	severity.
•	 Differential	expression	in	extracellular	vesicles	suggests	these	microRNAs	may	be	implicated	in	
the	pathology	of	aGvHD.
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inTrODUcTiOn
Graft-versus-host	disease	(GvHD)	is	a	major	cause	of	morbid-
ity	 and	mortality	 in	 hematopoietic	 stem	 cell	 transplantation	
(HSCT).	Despite	recent	advances,	the	incidence	remains	high	
(20–50%)	 and	GvHD	 therapy	 exacerbates	 infectious	 compli-
cations.	 Acute	 GvHD	 (aGvHD)	 classically	 develops	 in	 the	
first	3 months	post-HSCT	and	can	almost	double	the	cost	of	a	
transplant.	Thus,	a	novel,	non-invasive,	diagnostic	test	that	pre-
dicts	the	incidence	and	severity	of	aGvHD	would	enable	more	
timely	 prophylactic	 therapy,	 reducing	 morbidity,	 and	 health	
care	costs.
MicroRNAs	(miRNAs)	have	been	demonstrated	as	informa-
tive	 biomarkers	 for	 various	 diseases	 including	 inflammatory	
con	ditions	 and	 cancer.	miRNAs	 are	 small,	 non-coding	 single-
stranded	 RNAs,	 and	 regulate	 approximately	 50%	 of	 all	 genes,	
by	 binding	 to	 the	 3′UTR	 and	 repressing	 translation	 (1).	More	
recently,	 miRNAs	 have	 been	 identified	 in	 bodily	 fluids	 where	
they	are	protected	from	RNase-mediated	degradation	by	encap-
sulation	into	extracellular	vesicles	(EVs)	or	through	binding	to	
protective	proteins	[reviewed	in	Cortez	et al.	(2)].	These	miRNAs	
demonstrate	 a	 novel	 capacity	 to	 regulate	 the	 cellular	 differen-
tiation	 of	 blood	 cells	 and	 immune	 function	 (3).	 Furthermore,	
distinct	miRNA	expression	patterns	are	associated	with	specific	
pathophysiological	conditions	(4).
With	 regard	 to	GvHD,	miRNAs	 represent	 ideal	 candidates	
for	biomarker	identification	as	they	can	be	assessed	using	accu-
rate	and	sensitive	 technology	[e.g.,	quantitative	real-time	PCR	
(qRT-PCR)],	quantified	in	bodily	fluids	that	require	minimally	
invasive	sample	collection	(e.g.,	serum/urine),	and	further	inves-
tigated	for	biological	function	(e.g.,	target	protein	identification)	
that	 may	 expand	 upon	 our	 understanding	 of	 GvHD	 biology.	
Although	 the	field	 of	GvHD-related	miRNA	and	EV	 research	
is	 in	 its	 infancy,	 recent	 studies	 have	 demonstrated	 an	 emerg-
ing	 role	 for	miRNAs	 as	GvHD	 biomarkers.	 Indeed,	miR-155,	
an	 immune	 cell-related	 miRNA,	 is	 up-regulated	 in	 T-cells	
from	mice	 developing	 aGvHD	 following	HSCT,	 and	miR-155	
inhibitors	resulted	in	decreased	aGvHD	severity	and	prolonged	
survival	 (5).	 Furthermore,	 recent	murine	models	 have	 shown	
that	T regulatory	cells	(Tregs),	critical	cells	in	the	prevention	of	
auto-immunity,	can	modulate	effector	T-cell	 responses	via	 the	
release	of	EV	encapsulated	miRNAs	(6).
Xiao	 et  al.	 previously	 reported	 that	 a	 four	 miRNA	 plasma	
signature	 (miR-423,	 miR-199,	 miR-93*,	 and	 miR-377)	 could	
predict	the	probability	of	aGvHD	and	was	also	elevated	at	a	median	
of	 16  days	 prior	 to	 disease	 onset	 (7).	 In	 addition,	 the	miRNA	
signature	was	associated	with	aGvHD	severity	and	survival	(7).	
However,	the	data	have	not	been	replicated	in	an	independent	allo-
geneic	HSCT	(allo-HSCT)	cohort.	Furthermore,	serum	samples	
have	been	shown	to	demonstrate	higher	miRNA	expression	than	
plasma	(8),	while	expression	correlates	well	between	the	two	frac-
tions	 (9),	 indicating	 serum	may	be	 an	alternative	non-invasive	
fluid	for	biomarker	assessment.
This	study	sought	to	replicate	the	prognostic	and	diagnostic	
potential	 of	 miR-423,	 miR-199,	 miR-93*,	 and	 miR-377,	 by	
assessing	 expression	 in	 serum	 samples	 from	 HSCT	 patients	
taken	prior	to	disease	onset	[day	14	(D14),	prognostic	cohort],	
or	at	disease	presentation	(date	of	diagnosis,	diagnostic	cohort).	
To	 further	 explore	 the	 expression	 patterns	 of	 these	 miRNAs	
during	early	HSCT,	expression	was	assessed	in	serum	samples	
taken	at	 sequential	 time	points	 from	pre-transplant	 to	day	28	
post-HSCT.	 Finally,	 a	 novel	 investigation	 of	 miRNA	 expres-
sion	in	the	EV	fraction	of	serum	was	performed	at	sequential,	
prognostic,	 and	 diagnostic	 time	 points,	 in	 order	 to	 elucidate	
their	potential	role	in	circulating	microvesicles	during	aGvHD	
biology.
MaTerials anD MeThODs
clinical samples and ethics
The	 initial	 prognostic	 cohort	 comprised	 81	 allo-HSCT	 patient	
serum	 samples	 taken	 at	D14	post-HSCT,	 prior	 to	 the	 onset	 of	
aGvHD	 diagnosis.	 Sequential	 serum	 samples	 (D7	 pre-HSCT,	
D0,	D7,	D14,	and	D28)	were	available	for	a	subset	of	34	patients	
(sequential	 serum	 cohort),	 of	 which	 15	 were	 included	 in	 the	
EV	 sequential	 cohort.	The	 EV	 verification	 cohort	 included	 47	
independent	patient	serum	samples	taken	at	D14	post-HSCT.	All	
patients	were	 transplanted	 at	 the	Freeman	Hospital,	Newcastle	
upon	Tyne,	UK.	A	separate	diagnostic	cohort	of	serum	samples	
from	65	patients,	taken	at	the	time	of	aGvHD	onset	or	equivalent	
time	point	and	transplanted	at	the	Medical	University	of	Vienna,	
Austria	were	also	assessed.	Whole	blood	samples	were	collected	
at	D14,	time	of	aGvHD	onset	or	equivalent,	or	at	sequential	time	
points	 in	 7 ml	 vacutainers	 containing	 no	 anti-coagulant	 from	
patients	 undergoing	 allo-HSCT	 (years	 2008–2013).	 Clinical	
details	of	 the	cohorts	are	 shown	 in	Table 1.	All	blood	samples	
were	processed	immediately	upon	receipt,	whereby	they	were	left	
to	clot,	the	supernatant	centrifuged	at	500g	for	5 min	and	stored	
at	−80°C.	Serum	aliquots	were	centrifuged	at	4,500×g	for	15 min	
to	remove	platelets	before	use.
Patients	 consented	 to	 sample	 collection	 and	 molecular	
testing	 and	 the	 project	 was	 approved	 by	 the	 Newcastle	 and	
North	Tyneside	 I	 Research	Ethics	Committee	 and	 the	 Ethics	
Committee	 of	 the	Medical	University	 of	Vienna,	Austria.	All	
investigations	were	conducted	in	accordance	with	the	Helsinki	
Declaration.	The	overall	clinical	aGvHD	grade	was	established	
by	 clinicians	 in	 accordance	 with	 the	 NIH	 consensus	 and	
modified	 Glucksberg	 criteria	 (10,	 11).	 All	 the	 clinical	 data	
were	obtained	 from	 the	EuroTransplantBank	database	 (www.
EuroTransplantBank.org).
serum Total rna isolation
Total	 RNA	was	 isolated	 from	 250  µl	 serum	 using	 the	 Norgen	
Total	RNA	isolation	kit	(Norgen	Biotek),	following	the	suppliers	
instructions	in	Norgen	protocol	Appendix	B.
eV Precipitation and rna isolation
Extracellular	vesicles	were	isolated	from	250 µl	serum	using	Life	
Technologies	(LT)	total	Exosome	Isolation	Reagent,	according	
to	the	supplier’s	protocols.	The	EV	purity	was	initially	assessed	
by	 electron	microscopy	and	nanoparticle	 tracking	analysis,	 as	
previously	described	(12)	(Figure	S1	in	Supplementary	Material).	
All	 EV	 pellets	 were	 processed	 immediately	 for	 downstream	
TaBle 1 | Patient clinical characteristics.
Prognostic serum cohort (newcastle) Diagnostic serum cohort (Vienna) sequential eV cohort (newcastle) Verification eV cohort (newcastle)
characteristic all agvhD  
n (%)
no agvhD 
n (%)
p-Value all agvhD 
n (%)
no agvhD 
n (%)
p-Value all agvhD  
n (%)
no agvhD 
n (%)
p-Value all agvhD  
n (%)
no agvhD 
n (%)
p-Value
Patients 81 44 37 65 41 24 15 10 5 47 24 23
Agea
Average 49 46 53 0.09 47 45 49 0.33 48 44 54 0.16 49 49 49 0.93
Range 20–49 20–69 20–69 18–73 18–73 19–71 23–63 23–63 41–61 20–69 20–69 23–68
Genderb
Male 48 (59) 27 (61) 21 (57) 0.82 36 (55) 26 (63) 10 (42) 0.12 11 (73) 8 (80) 3(60) 0.56 23 (49) 13 (54) 10 (43) 0.56
Female 33 (41) 17 (39) 16 (43) 29 (45) 15 (37) 14 (58) 4 (27) 2 (20) 2 (40) 24 (51) 11 (46) 13 (57)
Conditioningb
Myeloablative 20 (25) 14 (32) 6 (16) 0.13 25c (44) 19 (53) 6(29) 0.10 3(20) 2(20) 1(20) 1.0 14 (30) 10 (42) 4(17) 0.11
Reduced intensity 61 (75) 30 (68) 31 (84) 32c (56) 17 (47) 15(71) 12 (80) 8 (80) 4(80) 33 (70) 14 (58) 19 (83)
Relationb
MUD 47 (58) 26 (59) 21 (57) 1.0 43c (75) 31 (78) 12 (60) 0.74 13 (87) 8 (80) 5 (100) 0.52 27 (57) 17 (71) 10 (43) 0.08
SIB 34 (42) 18 (41) 16 (43) 14c (25) 9 (22) 5 (40) 2 (13) 2 (20) 0 (0) 20 (43) 7 (29) 13 (57)
Survivalb
Alive 51 (63) 25 (57) 26 (70) 0.25 57 (88) 35 (85) 22 (92) 0.70 7 (47) 3 (30) 4 (80) 0.12 33 (70) 17 (71) 16 (70) 1.00
Deceased 30 (37) 19 (43) 11 (30) 8 (12) 6 (15) 2 (8) 8 (53) 7 (70) 1 (20) 14 (30) 7 (29) 7 (30)
Follow up (months)a
Average 11.5 11.8 11.5 0.96 50.9 51.9 49.9 0.99 12.4 14.4 9.1 0.31 11.0 9.7 12.3 0.32
Range 1.2–47.6 2.5–24.7 1.2–47.6 4.1–97.6 4.1–95.0 15.3–97.6 1.4–24.4 2.5–24.4 1.4–15.6 1.2–47.6 2.5–23.5 1.2–47.6
Clinical details of the prognostic (n = 81) and diagnostic (n = 65) serum cohorts, the sequential (n = 15) extracellular vesicle (EV), and verification (n = 47) EV cohorts to test for differences between acute graft-versus-host disease 
(aGvHD) versus no aGvHD groups. p-Values between groups were calculated using the independent two sample t-testa or Fishers Exact testb, as appropriate.
cSome clinical data unavailable.
MUD, matched unrelated donor; SIB, sibling donor.
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RNA	isolation.	The	EV	pellet	was	initially	re-suspended	in	lysis	
solution	 with	 the	 addition	 of	 100:1	 β-mercaptoethanol.	 RNA	
was	then	isolated	using	the	Norgen	Total	RNA	isolation	kit.
mirna qrT-Pcr
MicroRNA	 and	 endogenous	 control-specific	 cDNA	 [miR-423,	
miR-199-3p,	miR-93*,	and	miR-377,	HY3	and	U6	(12)]	was	gen-
erated	using	TaqMan®	MicroRNA	Assays	or	TaqMan®	Control	
Assays	 and	 the	 TaqMan®	 MicroRNA	 Reverse	 Transcription	
kit	 (LT),	 according	 to	 the	 supplier’s	 protocol.	 Each	 15  µl	 reac-
tion	 incorporated	 4  µl	 total	 RNA.	 qRT-PCR	 was	 performed	
incorporating	TaqMan®	MicroRNA	Assays	or	TaqMan®	Control	
Assays	(LT)	and	SensiFast	Probe	Hi-Rox	reagent	(Bioline).	Each	
10 µl	 reaction	 incorporated	3.25 µl	cDNA	and	 thermal	cycling	
was	performed	 in	 triplicate	using	 the	7900HT	Real-Time	PCR	
System	(LT),	according	 to	manufacturer	 recommended	cycling	
conditions.
statistical analysis
MicroRNA	expression	was	assessed	using	SDS2.4	software	(LT).	
Input	data	were	based	on	converted	ΔCt	values,	according	to	the	
comparative	Ct	 method	 (13).	 Statistical	 analyses	 were	 carried	
out	using	SPSS	v22.0,	Sigmaplot	v12.5,	or	GraphPad	Prism	v6.0.	
Graphs	were	produced	using	Sigmaplot	v12.5	or	GraphPad	Prism	
v6.0.	Differences	between	groups	were	assessed	using	the	Student’s	
t-test	(two	groups)	or	one-way	ANOVA	(less	than	two	groups).	
Homogeneity	of	variance	was	assessed	using	the	Levene	statistic.	
Following	a	significant	ANOVA	result,	differences	between	pairs	
of	groups	were	assessed	via	the	Tukey	post hoc	test	(SPSS	v22).	
Receiver	operating	characteristic	(ROC)	analysis	was	performed	
using	disease	 status	 as	 the	 binary	 state	 (classification)	 variable	
and	marker	expression	on	a	continuous	scale	as	the	test	variable	
(SigmaPlot	 v12.5).	 The	 ROC	 post-test	 results	 used	 a	 pre-test	
prior-probability	of	0.5	and	cost	ratio	of	1.0	(14).	The	optimal	cut-
off	value	to	dichotomize	miRNA	expression	was	computed	from	
sensitivity	and	specificity	using	the	slope	m	by	finding	the	cutoff	
that	maximizes	 the	 function:	 sensitivity − m	 (1 −  specificity)	
(SigmaPlot	v12.5)	(15).	The	accuracy	of	the	test	was	defined	by	
the	area	under	the	curve	(AUC)	whereby	AUC = 0.5	means	no	
diagnostic	ability	and	AUC = 1	means	perfect	diagnostic	abil-
ity.	 Principle	 components	 (PCs)	were	 calculated	 for	 correlated	
miRNAs	 using	 JMP®	 Pro	 v11.2.	 Correlation	 between	 miRNA	
expression	 was	 determined	 using	 Pearson’s	 correlation	 with	
Holm–Bonferroni	 multiple	 comparisons	 adjustment	 applied	
(16).	The	first	PC1	in	all	analyses	explained	the	majority	of	the	
variance	(range	63.5–78.2%)	and	thus,	was	used	 for	composite	
ROC	analysis.	The	weighting	used	in	PC1	for	each	miRNA	was	
derived	 from	eigenvectors	of	 the	 correlation	matrix.	PC1	 took	
the	form:	“Component	1 = (weighting1 * StdmiR1) + (weight-
ing2  *  StdmiR2)  +  …….”	 where	 “StdmiRX  =  ΔCtmiRx–
mean(ΔCtmiRx)/SD	 (ΔCtmiRx)”	 (JMP®	 Pro	 v11.2).	 Survival	 plots	
were	generated	using	the	Kaplan–Meier	method	and	differences	
in	 outcome	 were	 assessed	 for	 significance	 using	 the	 log-rank	
test	(SPSS	v22).	Cumulative	incidence	based	on	the	competing	
risk	method,	as	described	by	Fine	and	Gray	(17),	was	used	for	
assessing	the	association	between	miRNAs	and	both	relapse	and	
non-relapse	mortality	(18)	using	R	(R	Project)	package	“cmprsk”	
(competing	risks)	(19).
resUlTs
candidate mirna expression  
in Prognostic serum samples
The	initial	prognostic	cohort	was	comprised	of	serum	samples	
taken	 at	 D14	 post-HSCT,	 prior	 to	 the	 onset	 of	 symptomatic	
disease,	from	n = 81	HSCT	patients	who	later	developed	aGvHD	
versus	no	aGvHD	[aGvHD	n = 44	(54%),	mean	aGvHD	onset	
42  days	 post-HSCT]:	 [grades	 I =  5	 (6%),	 II =  31	 (38%),	 and	
III = 8	(10%);	no	aGvHD	n = 37	(46%)]	(Table 1).	Prophylactic	
therapy	 comprised	 of	 cyclosporine	 A	 (CyA)	 for	 all	 patients.	
No	treatment	for	aGvHD	had	been	given	at	the	time	of	sampling.	
There	was	no	significant	difference	in	patient	age	(p = 0.09),	gender	
(p = 0.82),	conditioning	regimen	(p = 0.13),	relationship	(p = 1.0),	
survival	(p = 0.25),	or	follow	up	(p = 0.96)	between	patients	who	
developed	aGvHD	compared	with	those	that	did	not	(Table 1).	
At	 the	 time	of	 follow	up,	n = 16	 (20%)	patients	were	 relapsed	
or	deceased,	n = 29	(36%)	had	NRM,	and	n = 35	(44%)	were	in	
remission.
Assessing	 expression	 of	 candidate	 miRNAs,	 miR-423	
(p < 0.001),	miR-199	(p = 0.04),	miR-93*	(p < 0.001),	and	miR-
377	(p = 0.03)	were	expressed	at	a	higher	level	in	patients	who	
developed	aGvHD	versus	no	GvHD	(Figure 1A).	Furthermore,	
ROC	 analysis	 identified	 miR-423	 (p  <  0.001,	 AUC  =  0.75),	
miR-199	(p = 0.09,	AUC = 0.62),	miR-93*	(p < 0.001,	AUC = 0.74),	
and	miR-377	(p = 0.03,	AUC = 0.66)	to	have	prognostic	ability	
with	regard	to	the	 incidence	of	aGvHD	(Figure 1B).	Assessing	
miRNAs	 in	 relation	 to	 aGvHD	 severity,	miR-423	 (p =  0.001),	
miR-199	(p = 0.01),	and	miR-93*	(p < 0.001)	were	expressed	at	
significantly	higher	 levels	 in	 severe	 (III–IV)	 versus	no	 aGvHD	
(Figure 1C).	miR-423	(p = 0.006)	and	miR-93*	(p = 0.01)	were	
higher	 in	mild	 (I–II)	 versus	no	 aGvHD	and	miR-199	was	 sig-
nificantly	 higher	 in	 severe	 (III–IV)	 versus	mild	 (I–II)	 aGvHD	
(p = 0.002)	(Figure 1C).	miR-377	expression	was	not	associated	
with	aGvHD	grade	(Figure 1C).	Assessing	miRNA	expression	in	
relation	to	clinical	factors,	there	was	no	significant	difference	in	
miR-423,	miR-199,	miR-93*,	or	miR-377	comparing	male	versus	
female	patients	or	reduced	intensity	(RIC)	versus	myeloablative	
conditioning	(p > 0.05)	(data	not	shown).	miR-423,	miR-199,	and	
miR-377	showed	no	difference	in	expression	comparing	sibling	
versus	matched	unrelated	donors	(MUD),	while	miR-93*	expres-
sion	 was	 higher	 in	 patients	 transplanted	 from	 MUD	 donors	
(p = 0.004)	(data	not	shown).
All	four	miRNAs	demonstrated	significant	positive	correlation	
in	expression	(p < 0.001–0.031;	R2 = 0.08–0.52)	and	this	remained	
significant	 after	 Holm–Bonferroni	 multiple	 testing	 correction	
(Figure	S2	 in	Supplementary	Material).	Due	to	significant	cor-
relation,	principle	component	analysis	(PCA)	was	performed	to	
calculate	a	composite	score.	The	first	PC1,	a	linear	combination	
of	miR-423,	miR-199,	miR-93*,	and	miR-377,	explained	63.5%	
of	 the	variability	 in	 the	data.	The	resultant	score	[PC1 =  (0.56
101 * StdmiR423) + (0.48296 * StdmiR199) + (0.53408 * Stdmi
R93*) + (0.40839 * StdmiR377)]	was	used	for	ROC	analysis	and	
FigUre 1 | MicroRNA (miRNA) expression in prognostic cohort patient serum samples. Expression of miR-423, miR-199, miR-93*, and miR-377 was assessed by 
quantitative real-time PCR at day 14 post-hematopoietic stem cell transplantation in the prognostic cohort (n = 81) and analyzed according to acute graft-versus-
host disease (aGvHD) occurrence and its severity. (a) miRNA expression according to aGvHD incidence. Box plot whiskers represent minimum to maximum 
expression and p-values were calculated using the independent two sample t-test. (B) Receiver operator characteristic curves for incidence of aGvHD to determine 
prognostic ability of miRNA expression. (c) miRNA expression according to aGvHD severity. Box plot whiskers represent minimum to maximum expression and 
p-values were calculated between groups using one-way ANOVA with Tukey post hoc multiple comparisons adjustment. *p < 0.05.
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showed	good	prognostic	ability	for	aGvHD	incidence	(p < 0.001,	
AUC = 0.74)	(Figure	S3A	in	Supplementary	Material).	There	was	
no	significant	association	with	OS	(p > 0.05),	however,	patients	
with	 a	 high-PC1	 score	 (≥0.44,	 the	 optimal	 dischotomization	
threshold	identified	by	ROC	analysis)	had	a	significantly	higher	
incidence	 of	 NRM	 (20-month	 probability	 of	 NRM	 57	 versus	
28%,	p = 0.04)	(Figure	S3D	in	Supplementary	Material).
candidate mirna expression in 
Diagnostic serum samples
In	order	to	explore	miRNA	diagnostic	potential,	expression	was	
assessed	in	an	independent	diagnostic	cohort	comprising	sam-
ples	taken	from	patients	at	the	time	of	aGvHD	onset,	or	equiva-
lent	time	point	for	patients	who	did	not	develop	aGvHD,	being	
treated	in	a	separate	Institution	(Vienna)	and	using	transplant	
center-specific	 treatment	 protocols.	 No	 treatment	 for	 aGvHD	
had	been	given	at	the	time	of	sampling.	The	cohort	comprised	
n = 65	HSCT	patients	[aGvHD	n = 41	(63%),	mean	onset	34 days	
post-HSCT:	grades	I = 22	(34%),	II = 5	(8%),	and	III = 14	(21%)],	
no	aGvHD	n = 24	(37%,	mean	time	of	sampling	42 days	post-
HSCT)	(Table 1).	Prophylactic	therapy	information	was	avail-
able	 for	 53/65	 (82%)	 patients	 [CyA + mycophenolate	mofetil	
(MMF)	n = 24	(45%),	CyA + methotrexate	(MTX)	n = 19	(36%),	
MTX	n = 7	(13%),	MMF	n = 2	(4%),	CyA	n = 1	(2%)].	There	
was	no	significant	difference	 in	patient	age	(p = 0.33),	gender	
(p = 0.12),	conditioning	(p = 0.10),	relationship	(p = 0.74),	or	
survival	 (p =  0.70),	 between	 patients	who	 developed	 aGvHD	
compared	with	those	that	did	not	(Table 1).
In	 this	 diagnostic	 cohort,	 miR-423	 (p  =  0.02),	 miR-199	
(p =  0.007),	 and	miR-93*	 (p =  0.004)	were	 expressed	at	 a	 sig-
nificantly	higher	 level	at	aGvHD	onset	 (Figure 2A).	There	was	
no	 differential	 expression	 of	 miR-377	 at	 the	 onset	 of	 aGvHD	
(p = 0.77)	(Figure 2A).	None	of	the	miRNAs	could	differentiate	
disease	severity	at	onset,	as	there	was	no	significant	difference	in	
expression	between	patients	with	mild	(grades	I–II)	versus	severe	
(grades	III–IV)	aGvHD	(p > 0.05)	(data	not	shown).	According	
to	 ROC	 analysis,	 miR-423	 (p =  0.03,	 AUC =  0.66),	 miR-199	
(p = 0.04,	AUC = 0.65),	and	miR-93*	(p = 0.01,	AUC = 0.68)	but	
FigUre 2 | MicroRNA (miRNA) expression in diagnostic cohort patient serum samples. Expression of miR-423, miR-199, miR-93*, and miR-377 was assessed by 
quantitative real-time PCR at the onset of acute graft-versus-host disease (aGvHD) symptoms, or equivalent time points for patients who did not develop aGcvHD, 
in the diagnostic cohort (Vienna, n = 65) and analyzed according to aGvHD incidence. (a) miRNA expression at aGvHD diagnosis according to aGvHD incidence. 
Box plot whiskers represent minimum to maximum expression and p-values were calculated using the independent two sample t-test. (B) Receiver operator 
characteristic curves for incidence of aGvHD to determine diagnostic ability of miRNA expression. *p < 0.05.
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not	miR-377	(p = 0.87,	AUC = 0.51)	had	diagnostic	ability	with	
regard	to	aGvHD	incidence	(Figure 2B).
All	three	diagnostic	miRNAs	demonstrated	significant	posi-
tive	correlation	(miR-423	versus	miR-199	p < 0.001,	R2 = 0.38;	
miR-423	 versus	 miR-93*	 p <  0.001,	 R2 =  0.54;	 and	 miR-199	
versus	miR-93*	p <  0.001,	R2 =  0.45)	 (data	not	 shown).	Thus,	
PCA	was	used	to	calculate	a	composite	score	and	PC1	explained	
78.2%	of	the	variability.	Composite	ROC	analysis	based	on	PC1	
[PC1  =  (0.57853  *  StdmiR423)  +  (0.55938  *  StdmiR199)  +  	
(0.59363 * StdmiR93*)]	showed	the	three	miRNA	model	to	have	
diagnostic	ability	with	respect	to	aGvHD	incidence	(p = 0.019,	
AUC = 0.68)	(Figure	S3B	in	Supplementary	Material).
candidate mirna expression in 
sequential serum samples
MicroRNAs	were	assessed	in	serum	samples	taken	at	sequential	
time	points	(pre-HSCT,	D0,	D7,	D14,	and	D28)	from	a	subset	of	
patients	of	the	prognostic	cohort	to	analyze	circulatory	expres-
sion	patterns	during	early	HSCT.	This	subset	comprised	n = 34	
HSCT	patients	[aGvHD	n = 19	(56%):	grades	I = 5	(15%),	II = 8	
(24%),	and	III = 6	(17%);	no	aGvHD	n = 15	(44%)]	(Table	S1	in	
Supplementary	Material).
Assessing	miRNA	expression	according	to	HSCT	time	points,	
miR-423	levels	were	elevated	from	the	day	of	transplant	(D0)	to	
D28	(D0	p = 0.04,	D7	p = 0.03,	D14	p = 0.03,	and	D28	p = 0.03)	
in	aGvHD	patients	compared	with	those	who	remained	aGvHD-
free,	while	miR-199,	miR-93*,	and	miR-377	expression	levels	were	
elevated	by	D14	(p = 0.06,	p = 0.04	and	p = 0.03,	respectively)	in	
patients	who	later	developed	aGvHD	(Figure 3A).
In	 all	 patients,	miRNA	expression	 in	 serum	 increased	 from	
pre-HSCT	 to	 D7	 post-HSCT	 (miR-423	 p  <  0.001,	 miR-199	
p < 0.001,	miR-93*	p < 0.001,	and	miR-377	p < 0.001),	followed	
by	a	decrease	in	expression	at	D14	(miR-423	p < 0.001,	miR-199	
p = 0.008,	miR-93*	p < 0.001,	and	miR-377	p < 0.001)	(Figure 3B).
In	relation	to	aGvHD	severity,	miR-423,	miR-199,	and	miR-
93*	were	differentially	expressed	at	D14	according	to	subsequent	
aGvHD	grade.	Specifically,	miR-423	was	expressed	at	a	signifi-
cantly	higher	level	in	patients	later	developing	aGvHD	(grades	
III–IV)	 versus	no	GvHD	 (p =  0.04)	 and	miR-199	 expression	
was	significantly	higher	in	patients	subsequently	experiencing	
aGvHD	(grades	III–IV)	versus	no	GvHD	(p = 0.007)	and	versus	
aGvHD	(grades	 I–II)	 (p = 0.03)	 (Figure 3C).	Similarly,	miR-
93*	expression	was	higher	in	patients	with	subsequent	aGvHD	
(grades	 III–IV)	 versus	 no	 aGvHD	 (p  =  0.08)	 (Figure  3C).	
MIR-377	expression	appeared	to	increase	according	to	aGvHD	
grade,	 but	 the	 differences	 were	 not	 statistically	 significant	
(Figure 3C).
candidate mirna expression in 
sequential eV samples
In	order	to	investigate	the	candidate	miRNAs	within	the	EVs	of	
serum,	expression	was	assessed	at	sequential	time	points	during	
early	HSCT	(pre-HSCT,	D0,	D7,	D14,	and	D28),	 in	a	subset	of	
15	patients	(Table 1).	miRNA	EV	expression	was	lower	at	D14	in	
patients	who	later	developed	aGvHD	compared	with	those	who	
did	not	and	this	was	significant	for	miR-199	(p = 0.008),	miR-93*	
(p = 0.001),	and	approaching	significance	for	miR-423	(p = 0.09)	
(Figure  4A).	There	was	 no	 significant	 difference	 in	 expression	
FigUre 3 | MicroRNA (miRNA) expression in sequential cohort patient serum samples. Expression of miR-423, miR-199, miR-93*, and miR-377 was assessed 
by quantitative real-time PCR and analyzed according to acute graft-versus-host disease (aGvHD) (a,B) incidence and (c) severity at sequential time points in 
n = 34 hematopoietic stem cell transplantation (HSCT) patients. (a) Patients were segregated based on the incidence of aGvHD and miRNA expression plotted 
at each time point. Differential miRNA expression between patients who developed aGvHD versus those who remained disease-free was assessed and significant 
or borderline differences are shown. Error bars represent mean with SEM and p-values were calculated using the t-test. (B) miRNA expression according to time 
point pre- and post-HSCT. Box plot whiskers represent minimum to maximum expression and p-values were calculated using the independent two sample t-test. 
(c) miRNA expression at day 14 according to aGvHD severity. Box plot whiskers represent minimum to maximum expression and p-values were calculated 
between groups using one-way ANOVA with Tukey post hoc multiple comparisons adjustment. *p < 0.05.
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of	miR-377	according	to	subsequent	aGvHD	incidence	(data	not	
shown).
Expression	of	miR-423,	miR-199,	and	miR-93*	was	compared	
between	serum	and	the	circulating	EV	fraction	for	matched	sam-
ples	(n = 15)	taken	at	time	points	pre-HSCT	to	D28	post-HSCT	
(Figure 4B).	Expression	patterns	showed	similarities	for	earlier	
time	points,	however,	by	D14	patients	who	did	not	subsequently	
develop	 aGvHD	 had	 markedly	 higher	 expression	 of	 miR-423	
(p = 0.03),	miR-199	(p = 0.009),	and	miR-93*	(p = 0.002)	in	the	
EV	fraction	compared	with	circulating	serum,	while	expression	
was	similar	in	patients	who	later	developed	aGvHD	(Figure 4C).
candidate mirna expression in 
Verification eV samples
Extracellular	vesicle	expression	of	miRNA	data	was	replicated	in	
an	independent	D14	verification	cohort	comprising	n = 47	HSCT	
patients	with	higher	grade	aGvHD	versus	no	aGvHD	[aGvHD	
n = 24,	grades	I = 0	(0%),	II = 22	(47%),	and	III = 2	(4%),	no	
aGvHD	n = 23	(49%)]	(Table 1).	There	was	no	significant	differ-
ence	 in	patient	age	(p = 0.93),	gender	(p = 0.56),	conditioning	
regimen	(p = 0.11),	relationship	(p = 0.08),	survival	(p = 0.10),	
or	follow	up	(p = 0.32)	between	patients	who	developed	aGvHD	
(mean	onset	38 days	post-HSCT)	compared	with	those	that	did	
not	(Table 1).
MicroRNA	EV	expression	at	D14	was	decreased	in	patients	
who	 later	 developed	 aGvHD	 compared	 with	 aGvHD-free	
patients,	 and	 this	 was	 significant	 for	miR-423	 (p =  0.02)	 and	
miR-199	(p = 0.04),	but	not	for	miR-93*	(p = 0.15)	(Figure 5A).	
In	 ROC	 analysis,	miR-423	 (p =  0.07,	 AUC =  0.66)	 and	miR-
199	(p = 0.08,	AUC = 0.66)	were	approaching	significance	for	
association	with	 risk	 of	 aGvHD,	while	miR-93*	 did	 not	 dem-
onstrate	 significant	 prognostic	 ability	 (p =  0.29,	AUC =  0.60)	
(Figure 5B).	Expression	of	miR-423	and	miR-199	 in	D14	EVs	
was	significantly	positively	correlated	(miR-423	versus	miR-199	
p < 0.001,	R2 = 0.55),	while	miR-423	and	miR-93*	demonstrated	
weak	 negative	 correlation	 (miR-423	 versus	miR-93*	 p =  0.02,	
R2 = 0.13)	and	miR-199	expression	did	not	correlate	with	miR-
93*	 expression	 (miR-199	 versus	miR-93*	p =  0.19,	R2 =  0.19)	
(data	 not	 shown).	 PC	 analysis	was	 calculated	 using	 predictive	
miRNAs	 (miR-423/miR-199)	 and	 PC1	 explained	 68.8%	 of	 the	
FigUre 4 | MicroRNA (miRNA) expression in sequential cohort patient extracellular vesicle (EV) and matched serum samples. Expression of miR-423, miR-199,  
and miR-93* was assessed by quantitative real-time PCR within serum and EVs and analyzed according to acute graft-versus-host disease (aGvHD) incidence  
in a sequential time points cohort (n = 15). (a) Patients were segregated based on the incidence of aGvHD, and EV miRNA expression plotted at each time point. 
Differential miRNA expression between patients who developed aGvHD versus those who remained disease-free was assessed and significant or borderline 
differences are shown. Error bars represent mean with SEM and p-values were calculated using the independent two sample t-test. (B) Comparisons between 
miRNA expression in EVs and matched serum samples (n = 15) at sequential time points, segregating patients based on the incidence of aGvHD. (c) miRNA 
expression at day 14 according to aGvHD incidence in whole serum (S) and the EV fraction (n = 15). Box plot whiskers represent minimum to maximum  
expression and p-values were calculated using paired t-tests. *p < 0.05.
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variability	in	the	data.	Using	PC1	[PC1 = (0.64068 * StdmiR423
) + (0.59539 * StdmiR199)]	for	composite	ROC	analysis	showed	
that	miR-423	and	miR-199	had	prognostic	potential	(p = 0.06,	
AUC = 0.69)	(Figure	S3C	in	Supplementary	Material).
miR-423,	miR-199,	and	miR-93*	expression	data	were	com-
pared	between	n = 47	matched	D14	samples	of	the	EV	verification	
and	 serum	 verification	 cohort.	 Similar	 to	 the	 previous	 smaller	
subset	 analysis	 of	 15	 sequential	 patients,	 at	 D14	 patients	 who	
subsequently	 did	 not	 develop	 aGvHD	had	 significantly	 higher	
expression	of	miR-423	(p = 0.02),	miR-199	(p < 0.001),	and	miR-
93*	 (p <  0.001)	 in	 the	 EV	 fraction	 compared	with	 circulating	
serum,	while	this	difference	was	less	marked	in	patients	who	later	
developed	the	disease	(miR-423	p = 0.03,	miR-199	p = 0.02,	and	
miR-93*	p = 0.04)	(Figure 5C).
DiscUssiOn
Recently,	circulating	miRNAs	within	the	serum	or	plasma	have	
been	shown	to	act	as	robust	biomarkers	for	a	variety	of	diseases.	
In	this	study,	expression	of	miR-423,	miR-199,	miR-93*,	and	miR-
377	was	assessed	in	circulating	serum	prior	to	aGvHD,	at	disease	
onset	and	at	sequential	HSCT	time	points,	and	associated	with	
FigUre 5 | MicroRNA (miRNA) expression in verification cohort patient extracellular vesicle (EV) and matched serum samples. Expression of miR-423, 
miR-199, and miR-93* was assessed by quantitative real-time PCR within serum EVs and analyzed according to acute graft-versus-host disease (aGvHD) 
incidence in the day 14 (D14) verification cohort (n = 47). (a) miRNA expression in the EV verification cohort at D14 according to aGvHD incidence. Box  
plot whiskers represent minimum to maximum expression and p-values were calculated using the independent two sample t-test. (B) Receiver operator 
characteristic curves in the EV verification cohort for incidence of aGvHD to determine prognostic ability of miRNA expression. (c) miRNA expression at D14 
according to aGvHD incidence in matched whole serum (S) and the EV fraction (n = 47). Box plot whiskers represent minimum to maximum expression and 
p-values were calculated using paired t-tests. *p < 0.05.
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predicting	disease	 incidence	 and	 severity.	The	 study	 is	 initially	
replicatory	in	nature,	in	order	to	validate	the	results	of	previous	
reports	 demonstrating	 the	 potential	 of	 circulatory	miRNAs	 as	
aGvHD	biomarkers	(7),	and	consequently	extends	these	data	into	
the	novel	field	of	EVs.
Unfortunately,	GvHD	has	remained	a	frequent	complication	
of	 HSCT.	 Diagnosis	 is	 typically	 based	 on	 clinical	 parameters	
confirmed	 by	 biopsy	 and	 thus,	 biomarkers	 are	 needed	 to	 aid	
in	predicting	disease	onset	and	 for	objective	diagnosis.	Plasma	
biomarkers,	 particularly	 proteins,	 have	 shown	 promise	 (20).	
However,	extensive	validation	is	required	to	improve	risk	stratifi-
cation	or	begin	customized	treatment,	and	protein-based	meth-
odology	can	be	insensitive	and	unsuitable	for	clinical	translation.	
In	contrast,	miRNAs	are	low	in	complexity,	expressed	specifically	
in	different	tissues,	and	biological	stages,	robust	and	can	be	accu-
rately	detected	by	common	laboratory	techniques	(8,	21).
Xiao	 et  al.	 reported	 that	 high	 expression	 of	 a	 four	miRNA	
model	 (miR-377,	 miR-423,	 miR-199,	 and	 miR-93*)	 was	
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associated	with	aGvHD	onset	and	poor	overall	survival	(7).	As	
with	 all	 potential	 biomarkers,	 however,	 replication	 is	 required	
in	 independent	 cohorts	 to	 confirm	 reproducibility,	 especially	
when	clinical	protocols	can	be	varied.	We	initially	assessed	the	
candidate	miRNAs	in	an	prognostic	cohort	of	D14	post-HSCT	
serum	samples	and	confirmed	the	results	of	Xiao	et al.,	demon-
strating	significantly	elevated	expression	of	miR-423,	miR-199,	
miR-93*,	and	miR-377	in	patients	who	subsequently	developed	
aGvHD,	and	their	prognostic	ability	by	ROC	analysis.	Xiao	et al.	
also	 assessed	 miRNA	 expression	 in	 matched	 patient	 samples	
taken	 before	 the	 onset	 of	 aGvHD	 (2  weeks	 post-HSCT)	 and	
after	the	onset	of	aGvHD	symptoms	(6 weeks	post-HSCT)	and	
observed	higher	expression	after	aGvHD	had	occurred	(7).	This	
may	 appear	 to	 be	 contradictory	with	 results	 of	 the	 sequential	
time	point	 expression	 analysis	 performed	 in	 our	 study,	where	
we	assessed	miRNA	expression	at	7-day	intervals	until	28 days	
post-HSCT	 and	 observed	 highest	 expression	 levels	 at	 day	 7,	
which	then	decreased	in	all	patients	regardless	of	aGvHD	status.	
However,	it	is	difficult	to	make	a	direct	comparison	between	the	
data	 sets	 without	 having	 a	 direct	 comparison	 of	 time	 points.	
Indeed,	expression	at	the	earlier	7-day	point	was	not	compared	
in	 the	 Xiao	 et  al.	 study,	 and	 additionally,	 the	 last	 time	 point	
assessed	 in	our	sequential	analysis	was	D28	post-HSCT,	while	
patients	developed	 aGvHD	at	 a	mean	onset	of	 42 days	 (prog-
nostic	 cohort)	 and	 34  days	 (diagnostic	 cohort)	 post-HSCT.	
According	to	our	data,	although	miRNA	expression	decreased	in	
all	patients	between	7	and	14 days	post-HSCT,	levels	between	14	
and	28 days	post-HSCT	remained	similar,	and	increased	in	the	
case	of	miR-377.	Is	it	not	inconceivable	that	if	a	comparison	was	
made	between	miRNA	expression	levels	pre-	and	post-aGvHD	
time	points	 in	 the	present	 study,	differences	may	be	observed.	
Xiao	et al.	also	reported	an	association	between	the	combined	
miRNA	model	and	poor	OS	(7).	Although	a	significant	associa-
tion	with	OS	was	not	identified	in	the	present	study,	the	model	
was	correlated	with	NRM,	suggesting	the	miRNAs	may	predict	
mortality	 from	causes	other	 than	relapse,	such	as	 incidence	of	
aGvHD.	In	an	independent	diagnostic	cohort	comprising	serum	
samples	taken	at	aGvHD	onset,	miR-423,	miR-199,	and	miR-93*	
were	 also	 elevated,	 further	 demonstrating	 their	 dysregulated	
expression	 in	 aGvHD	 and	 important	 biomarker	 potential.	
Although	data	demonstrated	by	Xiao	et al.	was	generated	using	
plasma	 samples,	 studies	 comparing	 the	 plasma,	 and	 serum	
fractions	of	blood	have	 suggested	a	high	degree	of	correlation	
in	miRNA	expression	 (8,	 9,	 22).	Thus,	 verifying	 the	 results	 of	
Xiao	et al.	in	an	alternative	sample	source	further	highlights	the	
reproducibility	of	the	data.
Xiao	 et  al.	 hypothesized	 that	 the	 candidate	 miRNAs	 may	
play	a	role	in	the	process	of	donor	T-cells	alloreactivity	against	
recipient	tissues,	or	in	response	to	damage	in	target	cells	during	
aGvHD,	 via	 selective	 inclusion	 into	 multivesicular	 bodies	 or	
exosomes	which	are	released	into	the	blood	stream.	In	the	present	
study,	the	EV	fraction	of	serum	was	investigated	in	sequential	
early	HSCT	time	points	and	results	replicated	in	a	larger	cohort	
of	D14	post-HSCT	samples.	Although	disadvantages	have	been	
reported	with	 the	 choice	of	 serum	compared	 to	plasma	as	 an	
EV	source,	such	as	clot	formation	during	the	serum	processing	
procedure	affecting	EV	release,	 either	by	 trapping	EVs	within	
the	clot	(23)	or	stimulating	releasing	platelet-derived	EVs	(24),	
serum	 samples	 are	 frequently	 utilized	 for	 optimization	 of	 EV	
isolation	and	analysis	techniques	(25–27).	It	has	been	suggested	
that	plasma	can	be	also	be	a	challenging	material,	due	to	high	
levels	of	clotting	factors	interfering	with	EV	precipitation	rea-
gents	(PRs),	leading	to	contaminating	proteins,	and	microvesi-
cles.	While	some	reports	suggest	no	difference	in	EV	isolation	
from	serum	or	plasma	(23),	additional	studies	are	required	 in	
order	to	fully	understand	how	EV	expression	might	be	affected	
by	sample	processing	protocols	(28).	In	this	regard,	the	present	
study	utilized	a	commercial	PR	for	serum	EV	isolation.	These	
reagents	are	relatively	new	to	the	market,	and	their	specificity	for	
EVs	remains	to	be	thoroughly	validated.	In	a	previous	study,	we	
demonstrated	the	LT	PR	to	recover	smaller	vesicles	than	a	com-
petitor	product,	 indicating	 improved	selectively	 for	small	EVs	
(12).	Other	studies	have	suggested	that	EV	pellets	isolated	using	
PR	are	free	from	contaminating	cell	organelles,	including	apop-
totic	bodies	(29)	and	that	the	method	recovers	more	EVs	than	
ultracentrifugation	(UC),	chromatography,	or	magnetic	beads,	
with	 higher	 EV	RNA	 and	 protein	 purity	 (30).	 Interestingly,	 a	
report	 specific	 to	 serum	 samples	 demonstrated	 low	 levels	 of	
protein-bound	 miRNA	 contamination	 in	 EVs	 isolated	 using	
PRs	 (27).	 Although	UC	 has	 historically	 been	 regarded	 as	 the	
gold	standard	for	EV	isolation,	the	practical	application	of	this	
method	is	limiting	with	regard	to	the	sample	volumes	required,	
length	of	 isolation,	 and	 requirement	 for	 specialist	 equipment.	
To	this	end,	PRs	have	been	evaluated	as	a	practically	applicable	
alternative	to	UC	in	a	clinical	setting	(31).	However,	despite	the	
acceptance	of	PRs	for	EV	isolation,	caution	must	be	applied	and	
it	would	be	 incorrect	 to	claim	 that	 the	 isolated	EV	pellets	are	
entirely	pure	in	nature.
The	EV	 aspect	 of	 this	 study	 is	 novel	 and	 extends	 upon	 the	
hypotheses	proposed	by	Xiao	et  al.	EVs	are	known	 to	 regulate	
cellular	 differentiation	 of	 blood	 cells,	 metabolic	 pathways,	
and	modulate	 immune	 function	 (3)	 and	play	 a	 role	 in	 antigen	
presentation	either	directly,	or	indirectly	via	transfer	to	antigenic	
peptides	or	by	cross-dressing	APCs	(32).	Upon	activation,	T lym-
phocytes	produce	large	amounts	of	EVs	that	bear	TCR	from	the	
pool	of	activated	complexes	(33)	and	it	is	possible	that	sub-sets	
of	T-cells	may	be	further	defined	by	their	EV	miRNome.	Indeed,	
20	intracellular	miRNAs	were	shown	to	distinguish	between	sub-
populations	of	CD4+	T-cells,	defining	the	development,	and	dif-
ferentiation	of	this	lineage	(34).	Furthermore,	CD4+CD25+Foxp3+	
Tregs	released	EVs	following	activation	in	a	mouse	model	(35)	
and	 CD8+CD25+Foxp3+	 T-cells	 secreted	 EVs	 that	 inhibited	
DC-induced	CD8+	CTL	responses	(36),	demonstrating	immune	
suppressive	capacities	for	these	EVs.
In	 the	present	 study,	 expression	of	 the	 candidate	miRNAs	
(miR-423,	 miR-199,	 and	 miR-93*)	 was	 lower	 in	 the	 EV	
fraction	 of	 patients	 who	 subsequently	 developed	 aGvHD.	
In	 comparison	 with	 serum,	miR-93*	 in	 the	 EV	 fraction	 did	
not	 show	 a	 strong	 association	 with	 aGvHD,	 suggesting	 this	
miRNA	may	not	be	differentially	packaged	into	serum	EVs	in	
an	HSCT	 setting.	 Patients	who	 did	 not	 develop	 aGvHD	had	
significantly	higher	levels	of	miRNAs	within	the	EV	fraction,	
and	we	hypothesize	 that	 these	miRNAs	are	being	 specifically	
transported	 in	 the	 circulation	 to	 distal	 target	 organs,	 where	
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they	function	in	an	aGvHD	protective	capacity.	However,	the	
relationship	between	miRNA	expression	 in	whole	serum	and	
the	 EV	 compartment	 is	 not	 completely	 understood,	 and	 the	
main	 source	 of	 circulatory	 miRNA	 carrier	 in	 serum	 is	 still	
debatable.	While	some	groups	have	reported	that	the	majority	
of	miRNAs	are	included	within	EVs	(37),	there	is	also	evidence	
to	 suggest	 that	miRNAs	 are	more	 commonly	 co-fractionated	
with	protein	complexes,	such	as	Argo-2	(38,	39).	To	add	further	
complication,	it	has	also	been	shown	that	the	mode	of	transport	
can	be	specific	to	individual	miRNAs,	for	example	an	HDL,	EV,	
or	Ago2	 carrier	 (39,	 40),	 and	 the	 factors	 determining	which	
mechanisms	 are	 used	 are	 also	 unclear.	 Finally,	 although	 it	 is	
well	recognized	that	specific	miRNA	populations	are	selectively	
sorted	in	to	EVs	(41),	current	research	suggests	four	potential	
mechanisms	 for	 this	 specific	packaging	 [nSMase2-dependent	
pathway,	 hnRNPs-dependent	 pathway,	 the	 3′end	 of	 the	
miRNA	sequence-dependent	pathway,	and	the	miRISC-related	
pathway	 (42)],	 and	 understanding	 of	 these	 processes	 in	 a	
cell-,	 tissue-,	 bio-fluid-,	 and	disease-specific	 context	 is	unex-
plored.	Altogether,	while	we	 have	 hypothesized	 explanations	
for	the	disparate	miRNA	expression	between	serum	and	EVs,	
this	remains	an	area	of	ambiguity,	but	likely	reflects	the	under-
lying	function	of	individual	miRNAs.
However,	identifying	the	biological	function	of	miRNAs	can	
be	 challenging,	 due	 to	 their	 short	 seed	 sequence	 potentially	
targeting	 hundreds	 of	 mRNA	 transcripts.	 miR-423,	 miR-199,	
and	miR-93*	have	suggested	roles	in	inflammation,	tissue	dam-
age,	regulation	of	cell	proliferation,	and	tissue	repair,	but	their	
specific	functions	in	an	aGvHD	setting	are	yet	to	be	elucidated	
(7).	miR-423	 has	 been	 implicated	 as	 a	 circulating	marker	 for	
heart	failure	(43)	and	promotes	cell	growth	by	regulating	G1/S	
transition	in	hepatocellular	carcinoma	via	p21Cip1/Waf1	(44).	
It	has	been	postulated	that	cell	cycle	progression	from	the	G1/S	
phase	may	 be	 a	 critical	 step	 for	 activation	 of	 immune-related	
cells	 in	 the	 pathogenesis	 of	GvHD.	Thus,	miR-423	 expression	
observed	 in	 this	 study	may	 function	 to	 regulate	Waf1,	 affect-
ing	 cell	 cycle	 progression.	 miR-199	 has	 also	 been	 shown	 to	
regulate	cell	proliferation	and	survival,	by	targeting	caveolin-2,	
a	 plasma	 membrane	 scaffolding	 protein	 involved	 in	 cellular	
growth	control,	and	apoptosis	(45).	Interestingly,	caveolin-1	has	
been	shown	to	regulate	TCR	signal	strength	and	Treg	differen-
tiation,	whereby	cav-1−/−	donor	T-cells	cause	less	severe	GvHD	
and	 yield	 higher	 numbers	 of	 Tregs	 (46).	 Caveolin-1	 and	 -2	
share	 structural	 similarities	 and	 are	 commonly	 co-expressed	
(45),	 however,	 miR-199	 regulation	 of	 caveolin-1	 is	 less	 well	
established	 in	 non-cell	 line	 material.	 miR-199	 has	 also	 been	
shown	to	regulate	mTOR	in	malignant	cells	(47–50).	In	GvHD,	
suppression	of	mTOR	by	rapamycin	 inhibits	 the	generation	of	
Th17 cells	and	enhances	TGF-β-induced	generation	of	FoxP3+	
Tregs	(51).	A	low	Th17/Treg	ratio	correlates	with	severe	clinical	
and	pathological	GvHD,	apoptosis	intensity,	and	TNF-α	expres-
sion	(52).	Accordingly,	high	 levels	of	Th17 cells	are	associated	
with	lethal	GvHD	in	mice,	hallmarked	by	extensive	pathologic	
cutaneous,	 and	pulmonary	 lesions	 (53),	while	 a	high	percent-
age	 of	 Treg	 cells	 is	 known	 to	 ameliorate	 aGvHD	 (54).	 Taken	
together,	this	may	suggest	a	protective	role	for	miR-199,	whereby	
increased	EV	expression	leads	to	target	cell	mTOR	suppression	
and	a	downstream	reduction	 in	aGvHD	severity.	miR-93*	has	
been	demonstrated	to	promote	tumor	growth	and	angiogenesis	
via	 targeting	 of	 integrin-B8	 (encoded	 by	 ITGB8)	 (55).	Mouse	
CD4+Foxp3+	Tregs	express	integrin-B8,	which	acts	as	a	marker	
for	 thymic-derived	 Tregs.	 Functionally,	 Tregs	 from	 ITGB8	
knockouts	(KO)	exhibit	normal	suppressor	function	in	in vitro	
and	in vivo	models	of	colitis,	but	fail	to	provide	TGF-β1.	ITGB8	
KO	Tregs	express	higher	surface	TGF-β1	levels,	consistent	with	
defective	 processing	 (56),	 and	 ITGB8	 KO	 mice	 demonstrate	
no	 suppressive	 ability	 against	 the	 innate	 or	 adaptive	 immune	
response	and	fail	to	reduce	the	level	of	inflammatory	cytokines	
(57).	In	breast	cancer	cell	lines,	Liu	et al.	demonstrated	that	miR-
93*	 induces	mesenchymal	epithelial	 transition,	associates	with	
downregulation	of	multiple	stem	cell	regulatory	genes	including	
JAK1,	 STAT3,	 and	EZH1	 (58).	Activated	 JAK1	 is	 required	 for	
T-effector	cell	responses	in	inflammatory	disease,	and	inhibition	
leads	to	improved	survival	of	mice	following	aGvHD,	reduced	
histopathological	grading,	and	 lower	 serum	pro-inflammatory	
cytokine	 levels	 (59).	 Associations	 with	 STAT3	may	 also	 have	
implications	 in	 aGvHD	 pathology,	 whereby	 the	 STAT3	 tran-
scription	factor	promotes	Treg	instability	and	is	increased	prior	
to	aGvHD	onset	(60,	61).	EZH1	is	also	implicated	in	mediating	
GvHD,	whereby	conditional	loss	of	EZH2	in	donor	T-cells	inhib-
its	GvHD	 in	mice,	 specifically	 impairing	T-cell	 differentiation	
into	IFN-gamma	producing	effector	cells	(62).	Studies	in	kidney	
have	shown	that	miR-93*	also	targets	vascular	epithelial	growth	
factor-A	(VEGF)	(63),	a	cytokine	associated	with	hematopoietic	
cancer	outcome,	immune	modulation,	and	tissue	repair	(64,	65).	
With	regard	to	GvHD,	VEGFA	levels	have	been	associated	with	
incidence	 of	 aGvHD	 (66),	 relapse,	 and	 non-relapse	mortality	
following	HSCT	 (64).	miR-377	 has	 been	 shown	 to	 suppresses	
cell	proliferation	by	targeting	CDK6,	a	cyclin-dependent	kinase	
that	regulates	G1/S	progression,	and	is	highly	overexpressed	in	
patients	 with	 GvHD	 (67).	 Interestingly,	 it	 was	 demonstrated	
that	miR-377	 expression	 is	 regulated	 by	CyA,	 an	 immunosup-
pressant	 drug	 commonly	 administered	 for	GvHD	prophylaxis,	
and	that	miR-377	inhibition	resulted	in	reduced	CyA-mediated	
apoptosis	(68).	It	would	be	interesting	to	assess	the	effect	of	CyA	
on	miR-377	expression	in	serum.	In	the	present	study,	miR-377	
was	 not	 replicated	 as	 a	 reproducible	 predictive	 biomarker	 and	
interestingly,	 all	 Newcastle	 patients	 with	 available	 information	
on	aGvHD	prophylaxis	received	CyA.
The	 increased	miRNA	 expression	 observed	 at	 day	 7	 post-
HSCT	 was	 an	 interesting	 finding	 of	 this	 study,	 particularly	
as	 levels	 remained	 higher	 in	 the	 patients	 who	 subsequently	
developed	aGvHD.	We	did	not	detect	any	significant	differences	
in	the	conditioning	regimens	between	patients	who	developed	
aGvHD	 compared	with	 those	 who	 did	 not,	 and	 so	 this	 can-
not	 explain	 the	 data.	 We	 hypothesize	 that	 elevated	 miRNA	
expression	at	day	7	in	both	aGvHD	and	no	aGvHD	patients	is	a	
reflection	of	an	elevated	inflammatory	reaction,	in	response	to	
the	initiation	of	HSCT	conditioning	regimens,	and	the	HSCT	
procedure.	 It	 is	 well	 established	 that	 mucosal	 barrier	 injury,	
induced	by	intensive	cytotoxic	therapy	prior	to	HSCT,	initiates	
the	 release	of	pro-inflammatory	 cytokines,	 chemokines,	 anti-
microbial	peptides,	and	the	acute	phase	protein,	LPS-binding	
protein	 (LBP)	 (69,	 70).	 Interestingly,	 serum	expression	 levels	
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of	 inflammatory	markers	 (CRP,	 IL-8,	 and	LBP)	peak	20 days	
following	 cytotoxic	 conditioning	 therapy,	 which	 corresponds	
to	1-week	post-HSCT	(70,	71).	Furthermore,	a	range	of	miR-
NAs	 are	 significantly	 elevated	 in	 serum	 post-chemotherapy	
(72).	miRNAs	 have	 been	 established	 as	 key	 regulatory	 factors	
in	wide	ranging	elements	of	immune	function	including	home-
ostasis,	response,	tolerance,	and	auto-immunity.	Furthermore,	
their	functionality	may	be	achieved	by	multiple	arrangements,	
including	a	linear	model	(one	miRNA	controlling	one	target),	
divergent	 model	 (single	 miRNA	 controlling	 multiple	 targets	
with	 distinct	 biological	 outcomes),	 network	 model	 (coordi-
nated	 regulation	 of	multiple	 targets	 with	 one	 outcome),	 and	
convergent	model	(many	targets	coordinated	by	cognate	miR-
NAs	 in	 a	 linear	manner,	 contributing	 additively	 to	 a	 specific	
response)	(73).	Taken	together,	this	highlights	the	significance	
of	miRNAs	as	 regulatory	 elements	 in	 the	 context	of	 immune	
response,	 and	 the	complexity	 surrounding	 trying	 to	decipher	
their	 expression	 and	 specific	 function	 in	 relation	 to	 immune	
response	activity.
As	 discussed,	 the	 miRNAs	 examined	 in	 the	 present	 study	
have	previously	been	associated	with	inflammation,	tissue	dam-
age,	regulation	of	cell	proliferation,	and	tissue	repair	and	thus,	
it	is	not	inconceivable	that	they	may	be	among	the	spectrum	of	
miRNAs	elevated	post-conditioning.	Although	it	is	not	clear	why	
these	miRNAs	remain	elevated	in	the	sub-group	of	patients	who	
develop	aGvHD	compared	with	those	who	remain	aGvHD-free,	
it	 is	 possible	 that	 this	 is	 a	 reflection	 of	 the	 escalating	 inflam-
matory	 cascade	 that	 occurs	 in	 patients	 who	 develop	 aGvHD.	
Indeed,	elevated	circulatory	miRNA	expression	may	initially	be	
driven	 by	 the	 conditioning	 and	 transplant	 procedure-initiated	
inflammatory	 reaction,	 which	 subsequently	 manifests	 into	 a	
cytokine	 storm	 and	 tissue	 damage,	 induced	 by	 alloreactive	
T-cells	of	donor	origin	in	patients	who	develop	aGvHD,	leading	
to	 sustained	miRNA	expression.	Conversely,	 the	 inflammatory	
reaction	diminishes	in	patients	who	do	not	develop	aGvHD	and	
miRNA	expression	may	 also	be	 reduced,	 if	 not	 further	 stimu-
lated	by	the	allogeneic	response	mediated	by	donor	T-cells.	This	
would	be	an	interesting	area	for	further	investigation.	Although	
Sun	et al.	performed	studies	in	mice	to	examine	miRNA	expres-
sion	patterns	in	allogeneic	T-cell	responses,	they	did	not	detect	
significant	 expression	 of	 the	miRNAs	 reported	 in	 the	 present	
study,	despite	homologs	being	present	on	the	miRNA	array	(74).	
However,	their	study	focused	on	allostimulated	T-cells	in vitro,	
while	 the	 present	 study	 concentrated	 on	 circulatory	 miRNA	
expression	in vivo.	Furthermore,	differences	in	miRNA	expres-
sion	 and	 function	 between	mouse	 and	 clinical	models	 cannot	
be	 ruled	 out.	 However,	 this	 does	 highlight	 the	 importance	 of	
comprehensive	miRNA	expression	profiling	in	the	aGvHD	set-
ting,	which	takes	into	account	both	the	full	array	of	recognized	
miRNAs	and	the	heterogeneity	 in	patient	 transplant	protocols.	
Indeed,	in	a	recent	study	we	performed	global	expression	profil-
ing	of	n = 799	mature	miRNAs	in	the	serum	of	aGvHD	patients	
(n  =  12)	 at	 aGvHD	 diagnosis	 (75),	 which	 incorporated	 an	
expanded	repertoire	of	miRNAs	compared	with	the	n = 345	spe-
cies	profiled	by	Xiao	et al.	(7).	Although	differential	expression	
of	 the	miR-423	and	miR-199	(miR-93*	was	not	present	on	the	
codeset)	 candidate	miRNAs	was	 confirmed,	 additional	 species	
with	highly	significant	differential	expression	were	also	 identi-
fied,	suggesting	that	a	panel	of	signature	miRNA	biomarkers	may	
be	a	more	potent	predictor	of	aGvHD	incidence	and	severity	for	
this	complex	disease.
In	conclusion,	this	study	has	replicated	circulating	miR-423,	
miR-199,	 and	miR-93*	 as	 diagnostic	 and	 prognostic	 biomark-
ers	 for	 aGvHD	 in	 independent	 cohorts.	 Principal	 component	
analysis	of	miR-423,	miR-199,	and	miR-93*	confirmed	the	utility	
of	the	miRNA	triad	in	predicting	occurrence	of	aGvHD.	In	addi-
tion,	 for	 the	first	 time	we	have	demonstrated	 the	expression	of	
these	miRNAs	 in	 the	EV	 fraction,	 and	 results	 suggest	 patients	
who	do	not	develop	 aGvHD	have	 a	higher	 level	within	 serum	
EVs	at	D14,	proposing	a	novel	predictive	biomarker	role	for	EVs.	
The	source	of	dysregulated	miRNA	expression	remains	unclear,	
particularly	 between	 donor-derived	 hematopoietic	 stem	 cells	
and	patient-derived	immune	response	cells,	and	this	represents	
an	important	area	for	further	investigation.	Further	assessment	
of	 the	 biological	 role	 of	 these	miRNAs,	 particularly	 in	 the	 EV	
compartment,	should	inform	on	their	contribution	to	the	devel-
opment	of	aGvHD.
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